What 8 Analyst Ratings Have To Say About Stryker

Providing a diverse range of perspectives from bullish to bearish, 8 analysts have published ratings on Stryker SYK in the last three months.

Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.

Analysts have set 12-month price targets for Stryker, revealing an average target of $371.0, a high estimate of $392.00, and a low estimate of $350.00. Marking an increase of 1.37%, the current average surpasses the previous average price target of $366.00.

Decoding Analyst Ratings: A Detailed Look

The standing of Stryker among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Stryker. This insight gives a snapshot of analysts' perspectives on the current state of the company.
• Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Stryker compared to the broader market.
• Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Stryker's stock. This examination reveals shifts in analysts' expectations over time.

Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Stryker's market standing. Stay informed and make well-considered decisions with our Ratings Table.

Stay up to date on Stryker analyst ratings.

Delving into Stryker's Background

Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, endoscopy systems, operating room equipment, embolic coils, hospital beds and gurneys, and spinal devices. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Just over one fourth of Stryker's total revenue currently comes from outside the United States.

Financial Milestones: Stryker's Journey

Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.

Revenue Growth: Stryker's remarkable performance in 3 months is evident. As of 31 March, 2024, the company achieved an impressive revenue growth rate of 9.73%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: Stryker's net margin is impressive, surpassing industry averages. With a net margin of 15.03%, the company demonstrates strong profitability and effective cost management.

Return on Equity (ROE): Stryker's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 4.17%, the company showcases efficient use of equity capital and strong financial health.

Return on Assets (ROA): Stryker's ROA stands out, surpassing industry averages. With an impressive ROA of 1.99%, the company demonstrates effective utilization of assets and strong financial performance.

Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.67.

Understanding the Relevance of Analyst Ratings

Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.

Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.

This article was generated by Benzinga's automated content engine and reviewed by an editor.